PL3924349T3 - Pochodne aminokwasów do leczenie chorób zapalnych - Google Patents

Pochodne aminokwasów do leczenie chorób zapalnych

Info

Publication number
PL3924349T3
PL3924349T3 PL20708296.7T PL20708296T PL3924349T3 PL 3924349 T3 PL3924349 T3 PL 3924349T3 PL 20708296 T PL20708296 T PL 20708296T PL 3924349 T3 PL3924349 T3 PL 3924349T3
Authority
PL
Poland
Prior art keywords
treatment
amino acid
acid derivatives
inflammatory diseases
inflammatory
Prior art date
Application number
PL20708296.7T
Other languages
English (en)
Inventor
Chao JIN
Daniel Paris
Michael Mullan
Original Assignee
The Roskamp Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Roskamp Institute filed Critical The Roskamp Institute
Publication of PL3924349T3 publication Critical patent/PL3924349T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL20708296.7T 2019-01-22 2020-01-22 Pochodne aminokwasów do leczenie chorób zapalnych PL3924349T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795549P 2019-01-22 2019-01-22
US201962871951P 2019-07-09 2019-07-09
PCT/US2020/014636 WO2020154420A2 (en) 2019-01-22 2020-01-22 Amino acid derivatives for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
PL3924349T3 true PL3924349T3 (pl) 2025-09-22

Family

ID=69726748

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20708296.7T PL3924349T3 (pl) 2019-01-22 2020-01-22 Pochodne aminokwasów do leczenie chorób zapalnych

Country Status (30)

Country Link
US (1) US20220081415A1 (pl)
EP (1) EP3924349B1 (pl)
JP (2) JP7784708B2 (pl)
KR (1) KR20210141930A (pl)
CN (1) CN113614074A (pl)
AU (2) AU2020211980B2 (pl)
BR (1) BR112021014372A2 (pl)
CA (1) CA3127246A1 (pl)
CL (1) CL2021001944A1 (pl)
CO (1) CO2021010931A2 (pl)
DK (1) DK3924349T3 (pl)
EC (1) ECSP21062210A (pl)
ES (1) ES3038582T3 (pl)
FI (1) FI3924349T3 (pl)
HR (1) HRP20251058T1 (pl)
HU (1) HUE072722T2 (pl)
IL (1) IL284980B1 (pl)
LT (1) LT3924349T (pl)
MA (1) MA54940B1 (pl)
MD (1) MD3924349T2 (pl)
MX (1) MX2021008748A (pl)
PH (1) PH12021551760A1 (pl)
PL (1) PL3924349T3 (pl)
PT (1) PT3924349T (pl)
RS (1) RS67095B1 (pl)
SG (1) SG11202107977TA (pl)
SI (1) SI3924349T1 (pl)
SM (1) SMT202500289T1 (pl)
WO (1) WO2020154420A2 (pl)
ZA (1) ZA202105229B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019389169A1 (en) 2018-11-30 2021-06-17 Comet Therapeutics, Inc. Cyclic pantetheine derivatives and uses thereof
WO2025144874A1 (en) 2023-12-24 2025-07-03 The Roskamp Institute Potent nf-kb inhibitors for the treatment of inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6262069B1 (en) * 1997-08-29 2001-07-17 Protherics Molecular Design Limited 1-amino-7-isoquinoline derivatives as serine protease inhibitors
US6218390B1 (en) 1998-12-17 2001-04-17 Synaptic Pharmaceutical Corporation Morpholinone and morpholine derivatives and uses thereof
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8710069B2 (en) * 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-nornicotine codrugs combinations for pain management
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
WO2010127058A1 (en) * 2009-05-01 2010-11-04 Profectus Biosciences, Inc. Benzamide and naphthamide derivatives inhibiting nuclear factor- kap pa (b) - (nf-kb)

Also Published As

Publication number Publication date
AU2025283544A1 (en) 2026-01-15
MA54940A (fr) 2021-12-22
EP3924349B1 (en) 2025-06-25
SI3924349T1 (sl) 2025-10-30
WO2020154420A3 (en) 2020-09-10
WO2020154420A2 (en) 2020-07-30
LT3924349T (lt) 2025-10-10
DK3924349T3 (da) 2025-09-08
MX2021008748A (es) 2022-01-24
MD3924349T2 (ro) 2025-11-30
SG11202107977TA (en) 2021-08-30
FI3924349T3 (fi) 2025-08-29
JP2025062004A (ja) 2025-04-11
CA3127246A1 (en) 2020-07-30
PT3924349T (pt) 2025-10-01
ES3038582T3 (en) 2025-10-14
US20220081415A1 (en) 2022-03-17
EP3924349A2 (en) 2021-12-22
AU2020211980A1 (en) 2021-08-19
CN113614074A (zh) 2021-11-05
HRP20251058T1 (hr) 2025-11-07
RS67095B1 (sr) 2025-09-30
SMT202500289T1 (it) 2025-11-10
PH12021551760A1 (en) 2022-05-30
AU2020211980B2 (en) 2025-09-18
CL2021001944A1 (es) 2022-05-06
IL284980B1 (en) 2026-05-01
KR20210141930A (ko) 2021-11-23
ECSP21062210A (es) 2022-06-30
JP7784708B2 (ja) 2025-12-12
JP2022524571A (ja) 2022-05-09
MA54940B1 (fr) 2025-09-30
BR112021014372A2 (pt) 2021-09-28
ZA202105229B (en) 2022-12-21
CO2021010931A2 (es) 2022-01-17
HUE072722T2 (hu) 2025-12-28
WO2020154420A4 (en) 2020-11-12
IL284980A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
IL279918A (en) Gene therapy vectors for treatment of danon disease
IL263174A (en) Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
EP3873897C0 (en) N-BENZOYL-PHENYLALANINE DERIVATIVES AS INTEGRIN ALPHA4BETA7 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
IL284125A (en) Quinoline derivatives for use in the treatment of inflammation diseases
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
HUE053115T2 (hu) Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére
HUE059638T2 (hu) Ízületi gyulladásos betegségek kombinált kezelése
IL269158A (en) Compositions and methods for treating inflammatory diseases
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
ZA202101587B (en) Protein for treatment of inflammatory diseases
IL281244A (en) Combination therapy for the treatment of liver disease
IL264603A (en) Reelin compositions for treatment of neurological disorders
ZA202105229B (en) Amino acid derivatives for the treatment of inflammatory diseases
IL280441A (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
EP3946348A4 (en) PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
IL272194A (en) Multispecific antibodies for use in treating diseases
PL3765055T3 (pl) Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych
IL288793A (en) Compounds for treating respiratory disease
EP4243802A4 (en) ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBROVASCULAR DISEASE
CY1126747T1 (el) Φαρμακο για την αγωγη λοιμωδων νοσηματων
DK3733684T3 (da) Ursodeoxycholsyre-derivater til behandling af polycystiske sygdomme